Medicus Pharma Commences Clinical Study for BCC Treatment in UAE

Medicus Pharma Ltd. announced the start of patient recruitment for the SKNJCT-004 Phase 2 clinical study at the Cleveland Clinic Abu Dhabi. This trial aims to evaluate a non-invasive treatment for basal cell carcinoma (BCC). Approval to proceed with the study was granted by the UAE Department of Health in May 2025.

The trial involves 36 participants across multiple sites in the UAE, including Sheikh Shakbout Medical City and Rashid Hospital. Managed by Insights Research Organization and Solutions, it will test two doses of D-MNA against a placebo. This initiative is seen as a step toward offering a novel BCC therapy.

Simultaneously, Medicus is conducting a parallel study in the U.S. and expanding collaborations, highlighted by a memorandum with Helix Nanotechnologies and the acquisition of Antev Limited.